IGC Pharma (IGC) said Thursday it has added Hamilton Health Sciences in Ontario, Canada, as a site for its ongoing phase 2 trial of IGC-AD1, its investigational cannabinoid-based therapy for agitation in Alzheimer's dementia.
The expansion is expected to support an increase in patient enrollment, the company said.
Shares of the company rose 2.8% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.